دورية أكاديمية

胰高血糖素样肽1受体激动剂类降糖药致2型糖尿病患者鼻咽炎和上呼吸道感染的网状 meta分析 ; Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper re-spiratory tract infection among patients with type 2 diabetes:a network meta-analy-sis

التفاصيل البيبلوغرافية
العنوان: 胰高血糖素样肽1受体激动剂类降糖药致2型糖尿病患者鼻咽炎和上呼吸道感染的网状 meta分析 ; Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper re-spiratory tract infection among patients with type 2 diabetes:a network meta-analy-sis
المؤلفون: 李志霞, 武珊珊, 杨智荣, 詹思延, 孙凤
المساهمون: 北京大学公共卫生学院流行病与卫生统计学系,北京,100191, 首都医科大学附属北京友谊医院国家消化系统疾病临床研究中心,北京,100050, Primary Care Unit,University of Cambridge,Cambridge CB2TN,UK
المصدر: CSCD ; 万方 ; 知网 ; http://d.g.wanfangdata.com.cn/Periodical_bjykdxxx201603014.aspxTest
بيانات النشر: 北京大学学报 医学版
سنة النشر: 2016
المجموعة: Peking University Institutional Repository (PKU IR) / 北京大学机构知识库
مصطلحات موضوعية: 胰高血糖素样肽1受体, 糖尿病,2型, 鼻咽炎, 上呼吸道感染, Meta分析, Glucagon-like peptide-1 receptor, Diabetes mellitus,type 2, Nasopharyngitis, Respirato-ry tract infections, Meta-analysis
الوصف: 目的:使用网状 meta 分析系统评价胰高血糖素样肽1受体激动剂(glucagon-like peptide-1 receptor ago-nists,GLP-1 RAs)类降糖药对两种常见的呼吸系统不良事件(respiratory system adverse event,RSAE,包括鼻咽炎和上呼吸道感染)的影响。方法:系统检索 Medline、Embase、Clinical trials 和 Cochrane 数据库中(截止2015年5月)比较 GLP-1 RAs 与传统降糖药或安慰剂对鼻咽炎和上呼吸道感染发生风险影响的随机对照研究,采用网状 meta 分析方法对纳入的研究结果进行加权合并。结果:共纳入50个研究,包括13种干预措施:7种 GLP-1 RAs 类药(艾塞那肽、艾塞那肽缓释剂、利拉鲁肽、利西拉来、他司鲁肽、阿必鲁肽、杜拉鲁肽)、5种传统降糖药(胰岛素、二甲双胍、磺脲类、西格列汀、噻唑烷二酮类)和安慰剂。网状 meta 分析结果显示,与胰岛素相比,他司鲁肽显著降低了鼻咽炎(OR =0.67,95%CI:0.46~0.96)和上呼吸道感染(OR =0.39,95%CI:0.23~0.73)的发生风险;与安慰剂相比,他司鲁肽显著降低了上呼吸道感染(OR =0.57,95%CI:0.34~0.99)的发生风险。此外,基于贝叶斯理论的网状meta 分析显示,鼻咽炎和上呼吸道感染发生风险排最末位的均为他司鲁肽。结论:他司鲁肽显著降低了鼻咽炎和上呼吸道感染的发生风险,但仍有待专门针对 RSAE 设计的大型前瞻性研究加以验证。 ; Objective:To systematically review the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)on two common respiratory system adverse events (RSAE:nasopharyngitis and upper re-spiratory tract infection)among type 2 diabetes (T2DM).Methods:Medline,Embase,Clinical trials and Cochrane library were searched from inception through May 201 5 to identify randomized clinical trials (RCTs)assessed safety of GLP-1 RAs versus placebo or other anti-diabetic drugs in T2DM.Network meta-analysis within a Bayesian framework was performed to calculate odds ratios for the incidence of RSAE.Results:In the study,50 RCTs were included,including 1 3 treatments:7 GLP-1 RAs (exenati-de,exenatide-long-release-agent,liraglutide,lixisenatide,taspoglutide,albiglutide and dulaglutide), placebo and 5 traditional anti-diabetic drugs(insulin,metformin,sulfonylureas,sitagliptin and thiazo-lidinediones ketones).Compared with insulin,taspoglutide significantly decreased the incidence of naso-pharyngitis (OR =0.67,95%CI:0.46 -0.96).Significant lowering effects on upper respiratory tract infection were found when taspoglutide versus placebo (OR =0.57,95%CI:0.34 -0.99)and insulin (OR =0.39,95%CI:0.23 -0.73).The result from the network meta-analysis based on Bayesian theo-ry could be used to rank all the treatments included,which showed that taspoglutide ranked last with ...
نوع الوثيقة: journal/newspaper
اللغة: Chinese
تدمد: 1671-167X
العلاقة: 北京大学学报(医学版).2016,48(3),454-459.; 1411317; http://hdl.handle.net/20.500.11897/445553Test
DOI: 10.3969/j.issn.1671-167X.2016.03.014
الإتاحة: https://doi.org/20.500.11897/445553Test
https://doi.org/10.3969/j.issn.1671-167X.2016.03.014Test
https://hdl.handle.net/20.500.11897/445553Test
رقم الانضمام: edsbas.CC9A710D
قاعدة البيانات: BASE
الوصف
تدمد:1671167X
DOI:10.3969/j.issn.1671-167X.2016.03.014